AVEO Oncology’s Post

In light of significant strides in cancer treatment and prevention, a diagnosis no longer carries the grim prognosis it once did.     Join us at #SXSW2024 for our “Rebranding Cancer” panel where experts will delve into reshaping the perception of cancer from one of fear to a more accurate portrayal of the advancements in oncology.    Learn more about our panel and download the Oncology Inflection here: https://bit.ly/3SPZBkd

Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach - ESMO - European Society for Medical Oncology https://lnkd.in/g8YDjY8Q #oncodaily #oncology #cancer #research #neoantigens #cancerimmunotherapy #immunotherapy

Are you willing to publish a short article in Cancerworld magazine? - European School of Oncology SPCC (Sharing Progress in Cancer Care) #AIInOncology #Cancer #Cancerworld #ESCO #OncoDaily #Oncology

#news This year’s #ASCO24 theme focuses on uncovering a world of inspiration.  Every year we are excited to join the oncology community at this crucial congress. At this year’s meeting we will be highlighting how #TeamBayer is inspired by those affected by cancer to drive innovative research in oncology. Learn more about Bayer’s commitment to transforming cancer care and addressing unmet patient needs across difficult-to-treat cancers: https://lnkd.in/ekY-krjA

The April issue of ONCOLOGY is available and ready to download. This month features a clinical quandary focused on testicular cancer, QAs with Drs Robert A Winn and Omid Hamid, and the letter to readers from Dr Neil M Iyengar. https://lnkd.in/ebiNjj2T #cancer #oncology

Winette van der Graaf shares key insights on advancing truly patient-centred clinical trials at American Society of Clinical Oncology (ASCO) - EORTC - European Organisation for Research and Treatment of Cancer European Cancer Organisation #ASCO24 #Cancer #CommonSenseOncology #EORTC #OncoDaily #Oncology

Today we barely scratch the surface of precision oncology, relying mostly on single-gene or single-protein markers to guide therapy. Cancer's biological complexity demands greater sophistication. One might envision a future where we use molecular signatures, AI-driven analytics, and other innovations to personalize treatment--but can our healthcare system handle this level of complexity, and how can innovators prosper if the market becomes increasingly fragmented? One might alternatively envision a future where we create better therapeutics that can act broadly with only simple biomarker guidance--but will ignoring much of cancer's complexity inevitably limit their impact for many patients? What vision should we strive for, and what will it take to achieve it? This is just a taste of the rich discussion we plan to have at this year's Emerging Frontiers in Oncology with our esteemed speakers. My co-planners--Uciane Scarlett, Prashant Girinath, Luke Timmerman, Jeff Bockman, Martin Strebl-Bantillo--and I are excited for it! Hope to see you there.

Join us and the FDA Oncology Center of Excellence September 6-7 for a virtual workshop addressing a critical issue in #oncology: dose optimization. #GettingtheDosageRight: Optimizing Dosage Selection Strategies in Combination Cancer Therapy will delve into the challenges and opportunities to improve dose selection, a topic that directly impacts the quality of life for people with cancer. Panelists include ASCO co-chair Dr. R. Donald Harvey and FDA co-chair Dr. Mirat Shah. Learn more and register: https://brnw.ch/21wC89g #GettingtheDoseRight23

Joint EANM‑SNMMI guideline on the role of 2‑[18F]FDG PET/CT in no special type breast cancer (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA) - Summary of the 2-[18F]FDG PET/CT recommendations according to the clinical scenario in NST breast cancer